ZimVie Announces Closing of Sale of Spine Business
01 Aprile 2024 - 2:00PM
ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the
dental market, today announced that it has closed the previously
communicated sale of its Spine business to an affiliate of H.I.G.
Capital for $375 million in total consideration, including $315
million in cash and a $60 million promissory note.
“The completion of the sale of our Spine business is the
culmination of months of partnership with H.I.G. Capital and years
of commitment from our global Spine team members; I would like to
thank everyone for their immense contributions,” said Vafa Jamali,
President and Chief Executive Officer. “I could not be more excited
for the future of our company as we continue to invest in
differentiated solutions for Dental patients and providers in our
most attractive end markets, while optimizing our structure to
deliver value for our shareholders.”
Terms of the Agreement
Under the terms of the agreement, ZimVie will receive $375
million in total consideration, comprised of $315 million in cash,
subject to certain customary adjustments as set forth in the
agreement, and $60 million in the form of a promissory note that
will accrue interest at a rate of 10% per annum, compounded
semi-annually, payable in kind, subject to a maturity no later than
five and a half years from today’s closing.
Outlook for ZimVie
As previously communicated, ZimVie expects to achieve an
annualized financial profile of $455+ million in Net Sales, and a
15%+ adjusted EBITDA margin(1) one year following the close of the
deal. ZimVie intends to immediately pay down $275 million of
outstanding debt, leaving total debt of approximately $234 million,
and estimated cash of approximately $66 million as of April 2,
2024.
(1) This is a non-GAAP financial measure for
which a reconciliation to the most directly comparable GAAP
financial measure is not available without unreasonable efforts.
Refer to the “Forward-Looking Non-GAAP Financial Measures” section
of this press release, which identifies the information that is
unavailable without unreasonable efforts and provides additional
information.
About ZimVie
ZimVie is a global life sciences leader in the dental market
that develops, manufactures, and delivers a comprehensive portfolio
of products and solutions designed to support dental tooth
replacement and restoration procedures. From its headquarters in
Palm Beach Gardens, Florida, and additional facilities around the
globe, ZimVie works to improve smiles, function, and confidence in
daily life by offering comprehensive tooth replacement solutions,
including trusted dental implants, biomaterials, and digital
workflow solutions. As a worldwide leader in this space, ZimVie is
committed to advancing clinical science and technology foundational
to restoring daily life. For more information about ZimVie, please
visit us at www.ZimVie.com. Follow @ZimVie on Twitter, Facebook,
LinkedIn, or Instagram.
Forward-Looking Non-GAAP Financial Measures
This press release also includes certain forward-looking
non-GAAP financial measures including adjusted EBITDA margin for
the period ending one year after the closing of the sale of our
spine business. We calculate forward-looking non-GAAP financial
measures based on internal forecasts that omit certain amounts that
would be included in GAAP financial measures. We have not provided
quantitative reconciliations of these forward-looking non-GAAP
financial measures to the most directly comparable forward-looking
GAAP financial measures because the GAAP measures cannot be
reliably estimated and the reconciliations cannot be performed
without unreasonable effort due to their dependence on future
uncertainties, such as the timing of certain transactions, and
adjusting items that the Company cannot reasonably predict at this
time but which may have a material impact on our future GAAP
results.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include,
but are not limited to, statements concerning ZimVie’s
expectations, plans, prospects and product and service offerings,
including expected benefits, opportunities, and other prospects as
a result of the transaction. Such statements are based upon the
current beliefs, expectations, and assumptions of management and
are subject to significant risks, uncertainties, and changes in
circumstances that could cause actual outcomes and results to
differ materially from the forward-looking statements. These risks,
uncertainties and changes in circumstances include, but are not
limited to, the possibility that ZimVie may be unable to achieve
the expected operational, strategic, and financial benefits of the
transaction. For a list and description of other such risks,
uncertainties, and changes in circumstances, see ZimVie’s periodic
reports filed with the U.S. Securities and Exchange Commission
(SEC). These factors should not be construed as exhaustive and
should be read in conjunction with the other cautionary statements
that are included in ZimVie’s filings with the SEC. Forward-looking
statements speak only as of the date they are made, and ZimVie
disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise. Readers of this press release are
cautioned not to rely on these forward-looking statements, since
there can be no assurance that these forward-looking statements
will prove to be accurate. This cautionary note is applicable to
all forward-looking statements contained in this press release.
Media Contact
Information:ZimVieAllison Johnson •
Allison.Johnson@ZimVie.com(774) 266-8046
ZimVieGrace Flowers •
Grace.Flowers@ZimVie.com(561) 319-6130
Investor Contact Information:
Gilmartin Group LLCMarissa Bych •
Marissa@gilmartinir.com
Grafico Azioni ZimVie (NASDAQ:ZIMV)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni ZimVie (NASDAQ:ZIMV)
Storico
Da Nov 2023 a Nov 2024